Tang Jiahua posted on a social networking site today (30th) that the EU has approved the emergency use of Oxford University/AstraZeneca vaccines before comprehensive data is available, describing it as “the attitude of a responsible public institution. Life is a matter of life, approved institutions You should not stick to the rules, but carefully weigh the risks of vaccine use.”
Xu Shuchang said that the EU approved the use of the AstraZeneca vaccine because the third phase of the data was published in the scientific journal “Lancet” in December last year, otherwise it would not be approved.
According to the information in this newspaper, AstraZeneca Vaccine published the interim analysis report of the third phase clinical study in Lancet on December 8 last year. It analyzed the data of approximately 12,000 participants out of approximately 24,000 The data comes from 4 clinical studies conducted in the UK, Brazil and South Africa.
When the European Medicines Agency announced on January 29 that it recommended to approve the AstraZeneca vaccine for emergency use in the EU, it said that it had made the decision after evaluating the quality, safety and efficiency of the vaccine, and mentioned that the relevant data came from the United Kingdom and Brazil. And 4 clinical studies in South Africa, the data is consistent with the data of the third phase of AstraZeneca clinical study.
New crown vaccine related reports:
The EU once restricted the vaccination from Ireland via the UK
Nie Dequan: Vaccination centers will be set up in 18 districts for at least half a year
–
